Orthofix (Nasdaq:OFIX) announced that it completed the full market release and first implants of its Legacy demineralized bone matrix (DBM).
Lewisville, Texas-based Orthofix designed the Legacy DBM as a putty for filling voids or gaps. It operates in boney defects or traumatic injuries of the spine, pelvis or extremities.
MTF Biologics processes the Legacy DBM, according to a news release. Its tailored processing methods preserve the inherent growth factors natural to the bone.
Dr. Alan Daniels, chief of spine surgery at University Orthopedics in Providence, Rhode Island, implanted the first patient.
“Bone healing is a dynamic process where multiple factors play an integral role in deciding which biologic best meets the individual needs of the patient to aid them on their road to recovery,” said Daniels. “Legacy DBM provides a cost-effective option, without compromising clinical experience or the handling needed in a bone matrix.”
RELATED: ZimVie Expands Navigation-Compatible Platform to Include Posterior Cervical Application
Orthofix adds to its growing portfolio
The puttylike consistency of Legacy DBM offers desirable handling, Orthofix said. Its uses include as an extender with autograft or allograft or with bone marrow aspirate. Legacy DBM joins a range of Orthofix’s recently introduced offerings through its exclusive partnership with MTF Biologics. That includes the Virtuous lyograft, Trinity Elite FiberFuse advanced and FiberFuse Strip allografts and the Alloquent structural allograft portfolio.
“The Legacy DBM is another example of our continued commitment to expand biologic offerings to meet the needs of surgeons and their patients. In the past year alone, we have introduced five new biologics including the Virtuos Lyograft, a first-of-its-kind, shelf-stable, and complete autograft substitute,” said Kevin Kenny, Orthofix president of global spine. “In addition, we recently announced a partnership with CGBio, a developer of innovative bone grafts, representing the first step in bringing Novosis – the next evolution in bone growth factor technology – to the U.S. and Canadian markets.
“We understand there are unique surgeon users for a wide range of bone-grafting options, and it is our goal to be a leading provider of these biologic offerings to our customers.”
The news comes just days after Orthofix announced a major merger in the orthopedic space. The company combined with SeaSpine in an all-stock merger of equals on Oct. 11.
Are you Hiring?
